Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns “Hold” Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note issued to investors on Monday,Benzinga reports.

LXRX has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $6.00.

Lexicon Pharmaceuticals Stock Performance

LXRX opened at $0.76 on Monday. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals has a 12-month low of $0.62 and a 12-month high of $3.73. The firm has a 50 day moving average of $1.14 and a two-hundred day moving average of $1.55. The firm has a market capitalization of $186.60 million, a PE ratio of -1.01 and a beta of 1.07.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The business had revenue of $1.75 million for the quarter, compared to analysts’ expectations of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same period last year, the business earned ($0.21) EPS. On average, analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CVI Holdings LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $34,000. Principal Financial Group Inc. raised its holdings in Lexicon Pharmaceuticals by 116.1% in the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 12,225 shares during the period. Great Point Partners LLC purchased a new position in Lexicon Pharmaceuticals during the second quarter worth approximately $50,000. BNP Paribas Financial Markets grew its holdings in Lexicon Pharmaceuticals by 71.2% in the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 13,246 shares during the period. Finally, Victory Capital Management Inc. increased its position in shares of Lexicon Pharmaceuticals by 44.5% in the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 13,972 shares in the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.